{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=durvalumab&page=20",
    "query": {
      "intervention": "durvalumab",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 453,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=durvalumab&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=durvalumab&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T11:44:52.023Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02669914",
      "title": "MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Nonsmall Cell Lung Cancer",
        "Breast Cancer",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Gastroesophageal Cancer",
        "Pancreatic Cancer",
        "Cancer of the Pancreas",
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Renal Cancer",
        "Kidney Cancer",
        "Cancer of the Kidney",
        "Cancer of Kidney",
        "Ovarian Cancer",
        "Ovary Cancer",
        "Cancer of the Ovary",
        "Cancer of Ovary"
      ],
      "interventions": [
        {
          "name": "MEDI4736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-09-12",
      "completion_date": "2018-01-11",
      "has_results": true,
      "last_update_posted_date": "2018-11-06",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02669914"
    },
    {
      "nct_id": "NCT04441138",
      "title": "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Non-small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-25",
      "completion_date": "2024-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04441138"
    },
    {
      "nct_id": "NCT05883644",
      "title": "Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 111,
      "start_date": "2023-06-27",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Shreveport, Louisiana • Detroit, Michigan",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05883644"
    },
    {
      "nct_id": "NCT02281084",
      "title": "Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Oral Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2015-07-06",
      "completion_date": "2023-09-14",
      "has_results": true,
      "last_update_posted_date": "2024-10-04",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 23,
      "location_summary": "New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281084"
    },
    {
      "nct_id": "NCT04585490",
      "title": "Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "NSCLC, Stage III",
        "Nsclc"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "AVENIO ctDNA Surveillance Kit",
          "type": "DEVICE"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2021-08-25",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04585490"
    },
    {
      "nct_id": "NCT04951115",
      "title": "A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-07-12",
      "completion_date": "2024-01-17",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 3,
      "location_summary": "Brooklyn, New York • Flushing, New York • New York, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Flushing",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04951115"
    },
    {
      "nct_id": "NCT02499328",
      "title": "Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "AZD9150",
          "type": "DRUG"
        },
        {
          "name": "MEDI4736",
          "type": "DRUG"
        },
        {
          "name": "AZD5069",
          "type": "DRUG"
        },
        {
          "name": "tremelimumab (treme)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 340,
      "start_date": "2015-08-06",
      "completion_date": "2025-10-08",
      "has_results": true,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02499328"
    },
    {
      "nct_id": "NCT04334759",
      "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mesothelioma",
        "Pleural Mesothelioma",
        "Malignant Pleural Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Standard Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab and Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PrECOG, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2021-02-18",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 25,
      "location_summary": "La Jolla, California • Miami, Florida • Tampa, Florida + 20 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04334759"
    },
    {
      "nct_id": "NCT04521686",
      "title": "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cholangiocarcinoma",
        "Chondrosarcoma",
        "Glioma",
        "Any Solid Tumor"
      ],
      "interventions": [
        {
          "name": "LY3410738",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2020-10-01",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04521686"
    },
    {
      "nct_id": "NCT03257761",
      "title": "Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Adenocarcinoma, Biliary Type",
        "Gallbladder Adenocarcinoma, Biliary Type",
        "Metastatic Pancreatic Adenocarcinoma",
        "Recurrent Cholangiocarcinoma",
        "Recurrent Gallbladder Carcinoma",
        "Recurrent Hepatocellular Carcinoma",
        "Recurrent Intrahepatic Cholangiocarcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Stage III Gallbladder Cancer AJCC V7",
        "Stage III Hepatocellular Carcinoma AJCC v7",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v7",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage IIIA Gallbladder Cancer AJCC v7",
        "Stage IIIA Hepatocellular Carcinoma AJCC v7",
        "Stage IIIB Gallbladder Cancer AJCC v7",
        "Stage IIIB Hepatocellular Carcinoma AJCC v7",
        "Stage IIIC Hepatocellular Carcinoma AJCC v7",
        "Stage IV Gallbladder Cancer AJCC v7",
        "Stage IV Hepatocellular Carcinoma AJCC v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IVA Gallbladder Cancer AJCC v7",
        "Stage IVA Hepatocellular Carcinoma AJCC v7",
        "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7",
        "Stage IVB Gallbladder Cancer AJCC v7",
        "Stage IVB Hepatocellular Carcinoma AJCC v7",
        "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7",
        "Unresectable Gallbladder Carcinoma",
        "Unresectable Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2018-02-07",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-24T11:44:52.023Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03257761"
    }
  ]
}